Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Southwest Airlines Stock Is Trading at Prices Too Low to Ignore

By Chris Lau, InvestorPlace Contributor

Yes, the airline industry is facing an uncertain future and sharp revenue loss. But LUV stock is trading at a price that's just too cheap.

Carnival Stock Will Survive and Thrive Even Without a Bailout

By Chris Lau, InvestorPlace Contributor

Investors expect Carnival to face steep losses ahead, as the coronavirus impacts demand. But CCL will survive and thrive in the long term.

7 Biotech Stocks to Buy That Could Beat the Coronavirus

By Chris Lau, InvestorPlace Contributor

These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure. Buy them now.

The Pending Mellanox Acquisition Will Sustain Nvidia Stock Here

By Chris Lau, InvestorPlace Contributor

NVDA stock fell along with the market but it has since rebounded. Its Mellanox acquisition will help it grow for several years.

Chesapeake Energy Stock Is Unlikely to Survive the Downturn

By Chris Lau, InvestorPlace Contributor

What happens in a bankruptcy? Shareholders in Chesapeake Energy will suffer as CHK stock essentially becomes worthless.

Load More